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Abstract 
Review on SASH1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: SH3D6A, dJ323M4, dJ323M4.1 




Entrez Gene: 23328 C, Ensembl: 
ENSG00000111961 C, UCSC: uc003qme.1 D, 
Vega:OTTHUMG00000015773. 
Description 
SASH1: located on human chromosome 6.  
Detailed gene locus: 6q24.3: 148593440-
148873186 (forward strand). 
ENSEMBL Database: Gene ID: 
ENSG00000111961. 
Transcription 
20 Protein-coding transcribed Exons, 7700 bp 
transcript, encoding 1247 amino acid residues. 
Pseudogene 
No known pseudogenes. 
Protein 
Note 
Human SASH1 is comprised of 1247 amino acid 
residues, with a pI of 5.7, and a molecular mass of  
137 kDa (please note that the apparent mass on 
denaturing SDS-PAGE is higher, roughly 170 kDa). 
SASH1 contains the following domains (from 
amino- to carboxyterminus): a predicted short 
coiled-coil stretch (CC), two predicted nuclear 
localisation signals (NLS1 and NLS2), a Src-
homology-3 domain (SH3, aa 557 - aa 614), a first 
sterile alpha motif (SAM1, aa 633 - aa 697), a 
proline-rich sequence (PPP, aa 978 - aa 1059), and 
a second sterile alpha motif domain (SAM2, aa 
1177 - aa 1241). 
Description 
Human SASH1 was first described in 2003 as 
putative tumor suppressor in breast cancer, it 
encodes a protein with both cytosolic and nuclear 
localisation.  
It lacks enzymatic activity, but, due to its multiple 
protein-protein interactions domains (SH3, SAM, 
poly-prolin stretches), it is likely to serve as a 
signal-adapter module that integrates and 
coordinates other proteins, thereby acting as a 
negative/positive signal transduction nodule. 
Expression 
SASH1 shows broad expression on protein level in 
human tissue and cell lines, as well as in mouse 
tissue.  
Exception: no or only weak expression has been 
found in lymphocytes. 
Localisation 
SASH1 is found both in the cytosol, as well as in 
the nucleus, with the exception of the nucleolus. 
Enrichment in membrane-proximal areas in 
migrating cells at the lamellipodia (Martini et al., 
2011). 
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Schematic Structure of the Exon structure of human SASH1, as compared to the other members of the SLY-family of 
signal-adapter proteins, SLy1 (SH3-protein expressed in lymphocytes), and SAMSN1 (or SLy2). At the bottom, the 
transcribed full-length protein is shown schematically. SASH1 is the largest member of the protein family, it is encoded by 20 
exons. All SLY-family proteins share a central conserved NLS (nuclear localisation signal) sequence, a SH3 and a SAM domain 
(dotted line). SASH1 comprises, in addition, a coiled-coil (CC) motif, a N-terminally located NLS signal (NLS2), a poly-prolin motif 
(PPP), and a second SAM domain at the C-terminus. 
 
 
Diagram schematically depicts human SASH1 protein (1247 aa), and the above-mentioned sequence-features: coiled-coil 
stretch (CC), nuclear localisation signals (NLS1 and NLS2), Src-homology-3 domain (SH3), a sterile alpha motif (SAM), a 




SASH1 has no intrinsic enzyme activity, but can 
form multi-protein complexes due to its protein-
protein interaction domains, and can modulate 
intracellular signal transduction. Moreover, SASH1 
is implicated in the regulation of cell adhesion and 
migration (Martini et al., 2011). 
Homology 
SASH1 belongs to the SLY-family, closest 
homologues: SLy1 and SLy2 (SH3-domain 
containing protein expressed in lymphocytes). Of 
note, SLy1 and SLy2 are much smaller (around 380 




Heterozygous germline mutations have been 
identified in the three nonconsanguineous families 
with benign dermatologic features in a Chinese 
study (Zhou et al., 2013). However, no correlation 
between these mutations and occurrence of 
malignoma has been reported so far:  
1) T → G substitution at nucleotide 2126 (TAC → 
GAC) in exon 14, resulting in amino acid 
substitutions of Tyr to Asp (Y551D) at codon 551  
2) T → C substitution at nucleotide 2019 (CTC → 
CCC) in exon 13, resulting in Leu to Pro at codon 
515 (L515P) 
3) G → A substitution (GAA → AAA) at position 
2000 in exon 13, causing Glu to Lys at codon 509 
(E509K). 
Somatic 
No truncating or nonsense mutations have been 
identified in somatic cells for SASH1 in a study on 




Loss of the gene-internal microsatellite DNA 
marker D6S311 was found in 30% of samples of 
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primary breast carcinoma, and the LOH was 
significantly correlated with poor survival and 
increase in tumor size. In established human 
mammary cancer cell lines, SASH1 is expressed at 
relatively low levels. SASH1 is downregulated in 
the majority (74%) of breast tumors in comparison 
with corresponding normal breast epithelia. In 
addition, SASH1 is also downregulated in tumors 
of the lung and thyroid. (Zeller et al., 2003). 
Colorectal cancer 
Note 
The mRNA as well as protein expression of SASH1 
was strongly and significantly reduced in colon 
cancer of UICC stage II, III, and IV, as well as in 
colorectal liver metastases. In contrast, SASH1 
expression was not significantly altered in benign 
adenomas and in early stage lesions (UICC I). 
Around 40% of primary colon tumours tested 
(n=113) showed a 10-fold or stronger reduction in 
SASH1 expression, compared to normal colon 
mucosa.  
Decreased SASH1 mRNA expression was 
correlated with the occurrence of metachronous 
distant metastasis, and multivariate analysis 
identified SASH1 downregulation as an 
independent negative prognostic parameter for 
patient survival (Rimkus et al., 2006). Recently, 
these results were confirmed on an independent 
patient collective of stage II colon cancer (n=179 
patients), confirming that decreased SASH1 
expression is an independent negative prognostic 
factor in colon cancer, allowing to distinguish high-
risk patients in early, locally restriced stages of the 
disease (Nitsche et al., 2012). 
Pancreatic cancer (unpublished 
observations) 
Note 
In a collective of n=103 patients with pancreatic 
ductal adenocarcinoma, 38% of the tumors showed 
no or strongly reduced SASH1 protein expression 
by immunohistochemistry. Decreased SASH1 
expression was significantly reduced with poor 
survival in Kaplan-Meier analysis (Tiago de 




SASH1 germline mutations have been identified in 
patients with a kind of dyschromatosis. Of note, 
three independent heterozygous germline mutations 
have been identified, that cause amino acid 
substitutions in the central SH3/SAM-containing 
region in the SASH1 gene. In epidermal tissues  
from an affected individual, increased 
transepithelial migration of melanocytes was 
observed (Zhou et al., 2013). 
Osteosarcoma 
Note 
SASH1 protein was significantly down-regulated in 
osteosarcoma tissues compared to normal bone 
tissue. Moreover, SASH1 protein showed 
significant down-regulation in osteosarcoma tissues 
from patients with lung metastasis compared to 
those without lung metastasis, and, lastly, a gradual 
decrease of SASH1 expression occurred with 
increasing Enneking stage (Meng et al., 2013).  
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